⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1427324 | 1.00 | — | — | |
| SCHEMBL1428054 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL25213388 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2904550 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL21820527 | 0.97 | — | — | |
| SCHEMBL14066206 | 0.92 | — | — | |
| SCHEMBL25040382 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL31328659 | 0.90 | SOS1 (0.34) | — | |
| SCHEMBL16925430 | 0.90 | ALDH1A1 (0.36) | — | |
| Formic Acid SCHEMBL30610903 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653436-A1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | GUANGZHOU YUFAN NANTU BIOTECHNOLOGIES CO., LTD (CN) | 2025-11-26 | — | — | EP | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| EP-4572755-A2 | CDK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4573094-A2 | CDK2 INHIBITORS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250101028-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE, LTD. (KY) | 2025-03-27 | — | — | US | disclosed |
| CN-119451681-A | Medicament containing vitamin D derivative or pharmaceutically acceptable salt or solvate thereof for use in combination with immunomodulatory substance | 帝人制药株式会社 | 2025-02-14 | — | — | CN | disclosed |
| US-20250051309-A1 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4499639-A1 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BeiGene, Ltd. (KY) | 2025-02-05 | — | — | EP | disclosed |
| CN-119241414-A | Vitamin D derivatives having cyclic amine in side chain | 帝人制药株式会社 | 2025-01-03 | — | — | CN | disclosed |
| US-20150087630-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | disclosed |
| EP-2300475-B1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH INC (US) | 2014-11-05 | — | — | EP | disclosed |
| CN-104059066-A | Diazacarbazoles And Methods Of Use | GENENTECH INC | 2014-09-24 | — | — | CN | disclosed |
| EP-2706059-A1 | Diazacarbazoles and methods of use | Genentech, Inc. (US) | 2014-03-12 | — | — | EP | disclosed |
| US-20130261104-A1 | METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER | GENENTECH, INC. (US) | 2013-10-03 | — | — | US | disclosed |
| US-8501765-B2 | Diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110118230-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2300475-A1 | DIAZACARBAZOLES AND METHODS OF USE | Genentech, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |